BioSpace News Archive

Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to three new employees.

Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today announced that it will give an oral presentation at the 2020 International Conference on Frailty and Sarcopenia (ICFSR) in Toulouse, France on March 12, 2020.

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report fourth quarter ended and year-ended December 31, 2019 financial results on Thursday, March 12, 2020.

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and other serious diseases, today announced that Dr. George Gittes, the lead researcher and Harvard graduate that developed Genprex’s new potentially curative diabetes gene therapy, was featured in a video interview discussing the therapy.

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido will present a company overview at the 32nd Annual ROTH Conference.

Biocept, Inc. (NASDAQ: BIOC) (“Biocept” or the “Company”), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, today announced that on March 4, 2020 it entered into a securities purchase agreement with several institutional investors.

COTA, Inc., a healthcare technology company that uses real-world data (RWD) to bring clarity to cancer care, today announced its board of directors has appointed C.K. Wang, M.D. as the company’s chief medical officer (CMO).

CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the “Company”), plans to release its results for the quarter and year ended December 31, 2019 , on Wednesday, March 11, 2020 after market close.

Nephrologists Partner with Nation’s Leading Provider of Kidney Care Products and Services to Improve the Future of Patient Care

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced the presentation of new data demonstrating that using Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo] to treat patients with intracranial hemorrhage (ICH) associated with the oral Factor Xa inhibitors apixaban or rivaroxaban is projected to provide a net reduction in costs to an acute care hospital